IMPORTANCE Borderline personality disorder (BPD) is a debilitating condition, but several psychotherapies are considered effective.
B orderline personality disorder (BPD) is a debilitating mental disorder characterized by severe instability in affect, identity, interpersonal relationships, and behavioral dysregulation. 1 Alongside a vast array of comorbidities, parasuicide (ie, nonlethal intentional self-harming behaviors) and suicide are commonly associated problems. More than 75% of patients with BPD are believed to engage in deliberate self-harm. 2 Suicide rates are estimated to be between 8% and 10%, 3, 4 almost 50 times higher than in the general population. 5 Borderline personality disorder is the most common personality disorder in clinical populations, 5, 6 associated with intensive use of mental health services 7, 8 even in the absence of a full diagnosis. 9 Functional impairment is considerable compared with other personality disorders 10 and is enduring in the absence of a change in personality psychopathology.
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Several psychotherapy approaches were specifically developed for the disorder, most notably dialectical behavior therapy (DBT), 12 cognitive behavior therapy (CBT), 13 and psychodynamic treatments, such as mentalization-based therapy 14 or transference-focused psychotherapy. 15 Each approach appeared to be more effective than treatment as usual (TAU) for BPD-related problems, such as suicidality or parasuicidal behavior. [16] [17] [18] [19] Trials of direct comparisons of treatments for BPD reported few differences among them. 20, 21 However, most trials demonstrating effectiveness were conducted with the direct participation of the treatment developer. Previous metaanalyses of psychotherapeutic treatments for BPD have been scarce and used focused criteria for assessing effectiveness, avoiding combining treatments. One meta-analysis 22 of DBT for BPD reported moderate effects for borderline-relevant outcomes, suicidality, and self-harm. However, analysis restricted to randomized clinical trials (RCTs) showed reduced effects, with nonsignificance for suicidality and self-harm. Another meta-analysis 23 of RCTs for BPD reported only moderate effects for the comparison between DBT and TAU. Conversely, because effectiveness differences between therapies appear to be limited and because variations of the same intervention are to be expected in diverse implementation settings, we believe that a broader effectiveness evaluation grouping therapies into theoretically intelligible categories is germane. Heterogeneity, publication bias, and potential moderators of efficacy (eg, treatment duration and type of psychotherapy) are additional unclear issues. Moreover, because the study collection dates of the 2 previous meta-analyses 22, 23 preceded 2012, new trials or follow-ups of older trials published since then should be considered. Therefore, our objective was to conduct an updated systematic review and metaanalysis of RCTs to assess the efficacy of psychotherapies for BPD-relevant outcomes at posttest and, where possible, at follow-up.
Methods

Identification and Selection of Studies
Studies were identified through searches in 4 bibliographical databases (from database inception to November 2015 in PubMed, PsycINFO, EMBASE, and the Cochrane Central Register of Controlled Trials) using the search term borderline personality (both text word and Medical Subject Headings term), with a filter for randomized trials (eMethods in the Supplement). We also checked the reference lists of earlier meta-analyses. 22, 23 Studies were included if they were RCTs in which a psychotherapy was compared with a control condition for adults diagnosed as having BPD. Given the diversity and complexity of therapy orientations, we used an inclusive approach in delineating the psychotherapy and control conditions. We used a customary definition of psychotherapy emphasizing verbal communication, structured and purposeful therapistpatient encounters, and the establishment of a therapeutic relationship. 24, 25 No constraints were placed on the control group, which could include (but was not restricted to) TAU or other treatments not specifically developed for BPD. Comparisons between 2 different psychotherapies specifically developed for BPD (ie, DBT and transference-focused psychotherapy) or between forms of the same psychotherapy (eg, DBT vs its skills training component) were excluded because of expectations of similar efficacy. Concomitant medication use was not an exclusion criterion unless it was prescribed in a standardized way, as in trials in which individuals were randomized to a combination of psychotherapy and either pharmacotherapy or placebo. Medication use followed a systematic protocol, and we could not disentangle its effects from those of psychotherapy. Studies on even partially adolescent samples were excluded because BPD diagnosis and treatment pose distinct challenges for this group. No language restrictions were applied. One researcher (I.A.C.) screened all records, and full texts were obtained for RCTs. Two independent assessors (I.A.C. and C.D.C.) examined the full texts and selected eligible RCTs.
generation of allocation sequence, (2) concealment of allocation to conditions, (3) prevention of knowledge of the allocated intervention to assessors of outcome (masking of assessors), and (4) dealing with incomplete data. This last domain was assessed as low risk if proper intent-to-treat (ITT) analyses were conducted, meaning that authors used a method for imputing missing values so that all randomized participants were included in the analyses. Masking of assessors was rated as low risk if the trial described proper methods of ensuring masking or if all relevant outcome measures were self-report instruments, thus not requiring the direct interaction with an assessor. For use in meta-regression analyses, we computed an overall RoB score for each study by awarding 1 point for each bias source rated as low risk. Among trials, we distinguished between stand-alone designs (in which the experimental group received a full course of an independent BPD psychotherapy and the control group received TAU or another therapy not specific for BPD) and add-on designs (in which both groups received TAU and the experimental group received an additional BPD therapy). We also extracted characteristics of the participants, interventions, and studies, including therapy type (DBT, psychodynamic, CBT, or other); control group (TAU, supportive therapy, or an ad hoc control, designed as part of the trial); whether the control group was manualized (ie, followed a treatment protocol or manual); involvement or noninvolvement of the study team in treating the control group; the presence or absence of a treatment developer as an author of the trial report; therapist supervision for the experimental group (by the treatment developer or by others); and low RoB (studies rated as low risk for ≤2 vs ≥3 RoB domains). We also extracted the following treatment intensity variables: treatment duration (in months), treatment exposure (in hours, calculated by multiplying the session duration for individual or group therapy by the number of sessions either planned or, if available, attended on average for the experimental and control groups), and difference in treatment exposure between the intervention and control groups (in hours). Risk of bias assessment and data extraction were performed by 2 independent assessors. Interrater agreement κ statistics were computed (eMethods in the Supplement), and disagreement was resolved by discussion among assessors and with the senior author (P.C.).
Meta-analysis
To capture the breadth and variability of reported outcomes, we grouped them into the following categories: borderline relevant (BPD symptom measures, self-harm and parasuicide, and suicidal behaviors), borderline symptoms (only BPD symptom measures), self-harm and parasuicidal behavior, suicidal behavior, health service use (hospitalizations [whether psychiatric or general], use of emergency services, use of additional outpatient services, and medication use), and general psychopathology (general psychopathology, anxiety, or depression). Treatment retention was computed as the comparative dropout rates between the intervention and control groups.
Dropouts (eMethods in the Supplement) were defined as all randomized participants not finishing treatment, regardless of the reasons. Adverse effects were defined as participant death by suicide and as death from any cause after randomization.
The between-group effect size was calculated as the difference between the intervention and control groups at posttest and at follow-up (Hedges g), corrected for small sample sizes. 27 Follow-up data more than 2 years from treatment termination or in which the control group also received the experimental treatment were not included. Data across multiple follow-up points were averaged at the study level for each outcome category. For treatment retention, odds ratios indicated the odds of maintaining participants in treatment in the intervention group vs the control group. If a trial reported data on multiple outcomes in the same category, the mean effect size was calculated using the procedures by Borenstein et al 28 so that each trial reported just one effect size in a category at each time point. Where available, the means (SDs) were used, but if only dichotomous outcomes were reported, we used available procedures 28 to compute the standardized mean difference. If a study did not include sufficient data for effect size calculation, the authors were contacted, and the study was excluded if they failed to provide data. Where available, ITT data were preferred. Effect sizes for dichotomous outcomes were computed, adhering to the ITT principle, by reporting the observed or imputed number of patients with an event (eg, self-harm) relative to the total number of patients randomized to that group. We used a software program (Comprehensive MetaAnalysis, version 3; Biostat) for computing and pooling effect sizes, with a random-effects model for pooling effect sizes. We calculated the number needed to treat using the formulas by Kraemer and Kupfer. 29 Heterogeneity was assessed with the I 2 statistic: 0% indicates no observed heterogeneity, and higher values indicate increasing heterogeneity, with 25%, 50%, and 75% defining thresholds for low, moderate, and high. We calculated 95% CIs around I 2 statistics 30 using a noncentral χ 2 -based approach (heterogi module for Stata, version 8; StataCorp LP). 31 Outliers were defined as studies in which the 95% CI was outside the 95% CI of the pooled studies (on both sides). For categorical moderators, we conducted subgroup analyses using a mixed-effects model. 28 For continuous moderators, meta-regression analyses used a restricted maximum likelihood model with the Knapp-Hartung method. 28 We examined publication bias through visual funnel plot inspection, the trim-and-fill procedure 32 (which produces an effect size estimate after accounting for publication bias), and Egger test for funnel plot asymmetry.
Results
Selection and Inclusion of Studies
We screened 1058 abstracts, removed 500 duplicates, and subsequently retrieved 158 full-text articles. Thirty-eight trials examined a psychotherapy, with 5 excluded for comparing 2 versions of the same therapy. Consequently, 33 trials (2256 participants) met our inclusion criteria, and 28 of them had enough data for calculating effect sizes (eFigure 1 in the Supplement). For the 5 missing trials, 20, [33] [34] [35] [36] the authors were contacted, but they did not provide the requested data.
Characteristics of Included Studies
The 33 trials included 1169 participants in the investigated treatment group and 1087 participants in the control group (eTable 1intheSupplement). Seventeen trials targeted patients with BPD diagnosed using a structured clinical interview, 10 trials targeted patients with BPD with recent documented selfharm, and the rest targeted special BPD populations (eg, veterans and individuals with addiction). Twenty-two trials had a stand-alone design, and 11 trials had an add-on design. Twelve trials had women-only samples, and this percentage ranged from 0% to 95% in the remainder. The best-represented approaches were DBT (12 trials), psychodynamic therapies (8 trials), and CBT (5 trials). Twenty-one trials had TAU as the control treatment, and the control treatment was manualized in 10 trials. The treatment developer was an author in 20 trials. In 15 trials, the treatment developer was a therapist or supervised therapists directly. Treatment duration ranged from 2.5 to 24 months, and the number of sessions (for individual and group therapy taken together) ranged from 6 to 312. The κ statistics indicated high interrater agreement for RoB estimations (eMethods in the Supplement), which were variable (eFigure 2 in the Supplement). Sixteen trials reported adequate sequence generation, 12 trials properly concealed allocation, and 20 trials implemented masking of outcome assessors (2 used self-report measures only). However, for incomplete outcome data, only 13 trials were rated as low RoB, and more than half had high RoB. Eleven trials could be rated as low risk on 3 or 4 domains.
Main Effects at Posttest
Stand-alone Designs Results showed significant effects for all outcome categories, ranging from 0.31 (0.04-0.57) for borderline symptoms to 0.44 (0.15-0.74) for suicide outcomes ( Table 1) . Heterogeneity was moderate to high with the exception of health service use. For all borderline-relevant outcomes (eFigure 3 in the Supplement), 17 trials had a Hedges g of 0.32 (95% CI, 0.14-0.51), with moderate heterogeneity (48%).
Add-on Designs
For borderline-relevant outcomes (Table 1 and eFigure 3 in the Supplement), 10 trials had a Hedges g of 0.40 (95% CI, 0.15-0.65), with moderate heterogeneity (50%). Results were not significant for self-harm and parasuicidal behavior or for health service use, but the number of trials was small (range, 3-6).
All Trials
Combining both design types for all borderline-relevant outcomes (combining borderline symptoms, self-harm and Figure) . Results with outliers excluded or excluding comparisons with supportive therapy were similar. For treatment retention, results were not significant for stand-alone designs (odds ratio, 1.32; 95% CI, 0.87-2.00 [15 trials]) or add-on designs (odds ratio, 1.01; 95% CI, 0.55-1.87 [10 trials]), and heterogeneity was moderate to high (59% for stand-alone designs and 44% for add-on designs). There were no significant differences between the 2 design types on any of the symptom outcome categories or on treatment retention.
Main Effects at Follow-up
Adverse Effects There were 2 deaths by suicide in the treatment group and 5 deaths by suicide in the control group. The treatment group and the control group each had 6 all-cause deaths.
Stand-alone Designs
Seven trials had a significant effect of 0.56 (95% CI, 0.17-0.95) for all borderline-relevant outcomes (Table 1) . Heterogeneity was high (62%). The number of trials was too small (range, [3] [4] [5] for the other outcome categories.
Add-on Designs
Six trials had a nonsignificant effect (g = 0.35; 95% CI, −0.15 to 0.85) for all borderline-relevant outcomes (Table 1) . Heterogeneity was high (79%). There were too few trials (range, [2] [3] [4] [5] in the other outcome categories.
All Trials
Combining both design types yielded a significant effect (g = 0.45; 95% CI, 0.15-0.75 [13 trials]) , with high heterogeneity (70%). These results are summarized in Table 2 and in eFigure 4 in the Supplement.
Subgroup and Meta-regression Analyses
Subgroup Analyses These analyses were conducted on the most inclusive outcome category (all borderline-relevant outcomes), combining stand-alone and add-on designs because we found no differences among them (Table 2 and Trials with an ad hoc control group developed as part of the study, trials in which the control intervention was manualized, or trials in which the study team was involved in treating the control group, as well trials with low RoB for 3 or 4 domains, generated nonsignificant between-group effects. Psychotherapies were more effective than control interventions in trials with more RoB than in those with less RoB (0.48 vs 0.11, P = .01).
Meta-regression Analyses
Risk of bias (the number of criteria with low RoB) had a significant negative association with outcomes at posttest (slope β = −0.16; 95% CI, −0.29 to −0.03; P = .02) (eFigure 5 in the Supplement). Dropout rates in the treatment group, treatment duration, treatment exposure in the treatment group or the control group, and difference in treatment exposure between groups were not significantly related to outcomes.
Publication Bias
Inspection of the funnel plot and the trim-and-fill procedure documented publication bias for borderline-relevant outcomes (eFigure 6 in the Supplement). At posttest, considering all trials, adjustment for missing studies (n = 6) decreased the effect size from a Hedges g of 0.35 (95% CI, 0.20-0.50) to 0.23 (95% CI, 0.07-0.38). For stand-alone designs, 4 studies were imputed, leading to a smaller but significant Hedges g of 0.20 (95% CI, 0.01-0.39). For add-on designs, 2 studies were imputed, resulting in a Hedges g of 0.30 (95% CI, 0.05-0.56). Egger test was not significant in any of these cases. At followup, considering all trials, adjustment for missing studies (n = 3) led to a nonsignificant Hedges g of 0.19 (95% CI, −0.15 to 0.53), and Egger test was significant (intercept β = 2.78; 95% CI, 0.18-5.39; P = .04).
Discussion
We conducted an updated systematic review and metaanalysis of RCTs of psychotherapies for BPD. We included 33 trials, either stand-alone designs (an independent experimental treatment vs TAU or another control) or add-on designs (an experimental treatment superimposed to TAU vs TAU alone). We examined disorder-specific outcomes (BPD symptoms, selfharm and parasuicide, and suicide) and more general outcomes, such as psychopathology or health service use. Most trials (22 of 33) had stand-alone designs, and our results showed significant, small, posttest between-group effect sizes, with high to moderate heterogeneity across all outcome categories. Results were more variable for add-on designs, including nonsignificant effects. Nonetheless, the number of trials for some outcome categories was small, and these findings should be viewed as tentative and possibly spurious. However, for borderline-relevant outcomes and psychopathology (for which most add-on trials included measures), effects were small to medium. We operated with this design distinction so as not to confound more intensive psychotherapeutic treatments with others designed to complement usual treatment, although subsequent subgroup analysis found no difference between the 2 design types on any of the outcome categories. We also found no differences between types of psychotherapies. Most trials focused on DBT followed by psychodynamic approaches, and both types generated significant, small between-group effect sizes, with low heterogeneity for DBT. Surprisingly, CBT was not superior to control conditions. Although this result was based on only 5 trials, heterogeneity was low. Follow-up results for all borderline-relevant outcomes showed significant medium effects for stand-alone designs and nonsignificant results for add-on designs. Heterogeneity was high, reflecting substantial differences in follow-up duration and type among trials, with some being naturalistic and others including booster interventions, which in some cases were intensive. 37 We did not include follow-up points more than 2 years after treatment termination because a longer time span increases the risk of biasing effects from factors extraneous to the intervention. Adverse effects were rare in both the experimental and control treatment groups. A surprising finding regarded treatment retention, for which we found no significant differences between the experimental treatment and control groups. This result remained stable for both design types and showed moderate heterogeneity. Improving treatment retention has generally Shown are standardized posttest effect sizes of comparisons between investigated psychotherapies and control conditions for borderline-relevant outcomes (borderline symptoms, self-harm and parasuicidal behavior, and suicide) for 27 trials. [16] [17] [18] [19] One meta-analysis 60 of treatment completion in BPD reported high treatment completion rates (approximately 75%) but with substantial betweenstudy heterogeneity. However, included studies were both observational and controlled trials, randomized or not. Unlike herein, the authors did not calculate differences in treatment completion between the experimental and control groups. Instead, they pooled absolute rates for the former, a procedure that is discouraged because it can lead to extremely high levels of heterogeneity.
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We further investigated the potential sources of heterogeneity in subgroup and meta-regression analyses. More than half of the trials included the treatment developer as an author, but they generated similar effects as independent trials. Yet a subtler effect potentially related to the involvement of the treatment developer emerged: differences between the experimental treatment and control groups were no longer significant in trials with an ad hoc control group developed as part of the study, where the control intervention was manualized, or where the study team was involved in treating the control group. We can speculate that, at least in part, the differential efficacy of psychotherapies designed for BPD in contrast to usual treatment could be due to the "special attention" granted to the experimental group or indeed to having a manualized, structured treatment. Nevertheless, treatment intensity (both treatment duration and exposure) was not related to the treatment outcomes considered.
Trial RoB consistently emerged as a moderator of effect sizes in both subgroup and meta-regression analyses. Trials with low RoB for at least 3 of the 4 domains considered generated nonsignificant effects for borderline-relevant outcomes. Moreover, there was a linear relationship between the number of criteria with low RoB and effect sizes: effects decreased by 0.16 for each additional domain that could be rated as low RoB. There was also evidence of publication bias for posttest results and particularly for follow-up. Its potential adjustment reduced effect sizes to smaller, albeit significant, values for both design types at posttest but to nonsignificant values for both design types at follow-up.
Limitations
Our meta-analysis has several limitations. Some outcome categories or subgroups included data from a small number of trials, rendering resultant effect sizes potentially uncertain. For 5 trials, we did not obtain access to data necessary for calculating effect sizes. Furthermore, most trials had not been registered in clinical trial registries, so we could not rate RoB because of selective outcome reporting. Our search was broad, but we may have missed trials that addressed personality disorders in general but ultimately had a sample composed of patients with BPD. Owing to the small number of trials, we grouped therapies in broader categories, effacing subtler differences between orientations. Frequently cited approaches, such as schema-focused therapy, were underrepresented, mainly because they were mostly studied in head-to-head trials. The use of adjunct medication was neither standardized nor consistently reported and could have confounded psychotherapy effects.
Conclusions
Various independent psychotherapies demonstrated efficacy for borderline-relevant symptoms, self-harm, suicide, health service use, and general psychopathology in BPD. However, effects were small, inflated by publication bias, and particularly unstable for follow-up. These effects were no longer sustained in trials with low RoB. While treatment intensity per se did not seem to influence outcomes, there are indications that a control group balanced for the involvement of the study team in treatment or with a manualized protocol is as effective as psychotherapies tailored for BPD. We found no evidence that treatment retention would be higher for specific psychotherapies than for control interventions, contradicting systematic claims from individual trials. Future trials should implement prospective registration in clinical trial registries. 
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Munroe-Blum H, Marziali E. A controlled trial of short-term group treatment for borderline personality disorder. J Pers Disord. 1995; 9(3):190-198. doi:10.1521 /pedi.1995 37. Bateman A, Fonagy P. Effectiveness of partial hospitalization in the treatment of borderline personality disorder: a randomized controlled trial. Am J Psychiatry. 1999;156 (10) Risk of bias (RoB) and data extraction Selective outcome reporting was not rated since inspection of the reports of the included trials revealed that only 6 out of 33 reported a trial registration number, 1 had a previously published protocol, and another referred to an unpublished one. Since trial registration is only the first step in looking at information for selective outcome reporting, we would have most likely been in the situation of rating most trials as unclear. The earliest of the six registered trials was conducted in 2008.
We also computed Cohen's Kappa inter-rater agreement for each of the four domains of the Cochrane Risk of Bias tool, prior to resolving disagreements. The Kappa inter-rater agreement coefficients were 0.88 for sequence generation, 0.95 for concealment of allocation, 0.90 for blinding for outcome assessors and 0.83 for dealing with incomplete data, showing high inter-rater agreement even prior to resolving disagreements.
Handling of dichotomous data
Dichotomous data was handled staying as true to the intent-to-treat (ITT) principle as possible. For dichotomous symptom outcomes (e.g., number of patients with self-harm, suicide attempts or hospitalizations), we used the imputed or observed number of patients with the event, reported in the original article (e.g., how many participants attempted suicide or were hospitalized in each group). In calculating group rates for the event, we reported this number to the total number of participants randomized in that group. Specifically, in the cases where the authors of the original trial performed imputation themselves to account for missing data, we used their imputed data. However, in the cases where they just provided the observed count for an event (e.g., how many hospitalized or with suicide attempts), we made sure that this number was reported to the number of participants initially randomized in the group in question (and not the number of participants who stayed in treatment or whom the authors for various reasons decided to retain in their analysis).
Drop-outs are a particular case of dichotomous outcome, because in this case it was generally possible to reconstruct patient level data. Drop-outs were defined as any participant who did not finish treatment., regardless of the reasons. We perused the report of the trial for all the information available regarding drop-outs post-randomization (the PRISMA diagram, information in the text and tables) so as to "reconstruct" the exact number of drop-outs. Again, this number was reported to the total number of randomized participants in each group. Note. a CBT, Cognitive Behavior Therapy; ctrl, control; DBT, Dialectical Behaviour Therapy; devel, developer; PDT, Psychodynamic Therapy; RoB, rating of Bias; TAU, treatment as usual; ST, supportive therapy; superv, supervisor.
b Represents the difference of treatment duration between the therapy and the control group, measured in hours -a positive score indicates treatment duration was longer for the treatment group. c Therapies classified as other included (in this order): Schema Focused Therapy (SFT), Emotion Regulation Group Intervention, Motive-oriented therapeutic relationship, SFT+DBT
